NDAINTRAVENOUSEMULSION
Approved
Aug 2008
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications (2)
Clinical Trials (1)
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
Started Jul 2023
Loss of Exclusivity
LOE Date
Oct 10, 2031
68 months away
Patent Expiry
Oct 10, 2031